Cargando…

Immunological recovery in patients with pulmonary tuberculosis after intensive phase treatment

OBJECTIVES: This study aimed to examine the change and significance of immune parameters in patients with sputum smear-positive pulmonary tuberculosis (TB) after 2 months of intensive phase anti-TB treatment. METHODS: The immune parameters of 232 cases of sputum smear-positive pulmonary TB were dete...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Xuejiao, Wu, Furong, Ma, Jun, Xiao, Heping, Cui, Haiyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136029/
https://www.ncbi.nlm.nih.gov/pubmed/29756540
http://dx.doi.org/10.1177/0300060518773258
_version_ 1783354928910041088
author Luo, Xuejiao
Wu, Furong
Ma, Jun
Xiao, Heping
Cui, Haiyan
author_facet Luo, Xuejiao
Wu, Furong
Ma, Jun
Xiao, Heping
Cui, Haiyan
author_sort Luo, Xuejiao
collection PubMed
description OBJECTIVES: This study aimed to examine the change and significance of immune parameters in patients with sputum smear-positive pulmonary tuberculosis (TB) after 2 months of intensive phase anti-TB treatment. METHODS: The immune parameters of 232 cases of sputum smear-positive pulmonary TB were detected before and after 2 months of intensive phase anti-TB treatment and compared with 50 cases from healthy volunteers (controls). The T lymphocyte cell population in peripheral blood was detected using flow cytometry. Serum levels of interleukin (IL)-1β, soluble interleukin-2 receptor, IL-6, and tumour necrosis factor-α were measured by ELISA. RESULTS: After 2 months of intensive phase anti-TB treatment, a reduction in the percentage of CD4+ T cells showed a significant restoration similar to that of controls. Moreover, after intensive anti-TB treatment, serum levels of IL-1β, soluble interleukin-2 receptor, IL-6, and tumour necrosis factor-α were significantly decreased compared with before treatment. Additionally, serum levels of IL-1β and IL-6 showed a diminished recovery compared with controls. CONCLUSIONS: Our findings suggest immunological recovery in patients with pulmonary TB after intensive phase treatment. Therefore, serum cytokine levels are considered potential host biomarkers for monitoring the response of treatment for pulmonary TB.
format Online
Article
Text
id pubmed-6136029
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-61360292018-09-17 Immunological recovery in patients with pulmonary tuberculosis after intensive phase treatment Luo, Xuejiao Wu, Furong Ma, Jun Xiao, Heping Cui, Haiyan J Int Med Res Clinical Research Reports OBJECTIVES: This study aimed to examine the change and significance of immune parameters in patients with sputum smear-positive pulmonary tuberculosis (TB) after 2 months of intensive phase anti-TB treatment. METHODS: The immune parameters of 232 cases of sputum smear-positive pulmonary TB were detected before and after 2 months of intensive phase anti-TB treatment and compared with 50 cases from healthy volunteers (controls). The T lymphocyte cell population in peripheral blood was detected using flow cytometry. Serum levels of interleukin (IL)-1β, soluble interleukin-2 receptor, IL-6, and tumour necrosis factor-α were measured by ELISA. RESULTS: After 2 months of intensive phase anti-TB treatment, a reduction in the percentage of CD4+ T cells showed a significant restoration similar to that of controls. Moreover, after intensive anti-TB treatment, serum levels of IL-1β, soluble interleukin-2 receptor, IL-6, and tumour necrosis factor-α were significantly decreased compared with before treatment. Additionally, serum levels of IL-1β and IL-6 showed a diminished recovery compared with controls. CONCLUSIONS: Our findings suggest immunological recovery in patients with pulmonary TB after intensive phase treatment. Therefore, serum cytokine levels are considered potential host biomarkers for monitoring the response of treatment for pulmonary TB. SAGE Publications 2018-05-13 2018-09 /pmc/articles/PMC6136029/ /pubmed/29756540 http://dx.doi.org/10.1177/0300060518773258 Text en © The Author(s) 2018 http://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Clinical Research Reports
Luo, Xuejiao
Wu, Furong
Ma, Jun
Xiao, Heping
Cui, Haiyan
Immunological recovery in patients with pulmonary tuberculosis after intensive phase treatment
title Immunological recovery in patients with pulmonary tuberculosis after intensive phase treatment
title_full Immunological recovery in patients with pulmonary tuberculosis after intensive phase treatment
title_fullStr Immunological recovery in patients with pulmonary tuberculosis after intensive phase treatment
title_full_unstemmed Immunological recovery in patients with pulmonary tuberculosis after intensive phase treatment
title_short Immunological recovery in patients with pulmonary tuberculosis after intensive phase treatment
title_sort immunological recovery in patients with pulmonary tuberculosis after intensive phase treatment
topic Clinical Research Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136029/
https://www.ncbi.nlm.nih.gov/pubmed/29756540
http://dx.doi.org/10.1177/0300060518773258
work_keys_str_mv AT luoxuejiao immunologicalrecoveryinpatientswithpulmonarytuberculosisafterintensivephasetreatment
AT wufurong immunologicalrecoveryinpatientswithpulmonarytuberculosisafterintensivephasetreatment
AT majun immunologicalrecoveryinpatientswithpulmonarytuberculosisafterintensivephasetreatment
AT xiaoheping immunologicalrecoveryinpatientswithpulmonarytuberculosisafterintensivephasetreatment
AT cuihaiyan immunologicalrecoveryinpatientswithpulmonarytuberculosisafterintensivephasetreatment